The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $424,875 Project Grant under CFDA 93.853 "Extramural Research Programs in the Neurosciences and Neurological Disorders" to the University of Maryland, Baltimore to conduct research on the role of the TREM2 gene and mitochondrial function in microglia, the immune cells of the brain. The key objectives are to elucidate mitochondrial defects in TREM2-deficient human microglia, determine if the drug idebenone can...
This federal Project Grant award of $2,833,089 was provided by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to the J. David Gladstone Institutes. The award will support research to investigate the roles of the TREM2 and TYROBP genes and their impact on network hyperexcitability, which may contribute to cognitive decline in Alzheimer's disease and related dementias. Key objectives include determining whether TYROBP hypofunction exacerbates network...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $757,027 to the University of Washington to conduct research on the synergistic relationship between tau and TDP-43 proteins in Alzheimer's disease. The research aims to identify mechanisms that drive the interaction between these two pathological hallmarks of Alzheimer's and how they contribute to cognitive decline and neurodegeneration. Key activities include using C. elegans models to...
This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $768,131 over 5 years to the University of California, San Diego (UCSD) to investigate the role of the TREM2 protein in Alzheimer's disease pathogenesis among people living with HIV. The project aims to delineate the specific mechanisms by which HIV infection may alter TREM2 function, potentially exacerbating neurodegeneration and inflammation and accelerating...
This Project Grant award from the National Institute on Aging's Aging Research federal grant program (CFDA 93.866) provides $871,419 to the University of Washington to conduct research on the role of microglia, the brain's immune cells, in the pathogenesis of Alzheimer's disease. The research aims to characterize molecular profiles and spatial organization of microglia across the adult age spectrum, both with and without Alzheimer's disease, through single-nucleus RNA sequencing of over 5,000...
This Project Grant award from the National Institute on Aging's (NIA) Aging Research program (CFDA 93.866) provides $104,164.00 to Emory University to explore the role of the TMEM106B gene in neurodegeneration. The project will examine the interaction between TMEM106B and the C9ORF72 gene, which is linked to frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Additionally, the research will investigate the toxicity of TMEM106B protein aggregates and their potential...
The National Institutes of Health's National Institute on Aging awarded a $7,432,562 project grant to the Regents of the University of California, San Francisco on September 15, 2022 under the Aging Research program (CFDA 93.866). The grant will support research to elucidate the roles of Alzheimer's disease risk genes and variants in gene expression and AD-related phenotypes through 2025. Specifically, the University of California, San Francisco will use CRISPR and single-cell RNA sequencing...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support Emory University's research into the genetic regulation of brain transcriptomics and proteomics associated with Alzheimer's disease and related dementias. The $528,876 award, effective June 1, 2025, will fund the development of new analytic tools to integrate genomic data across multiple tissues and improve the identification of genetic risk factors and underlying molecular mechanisms for...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will provide $429,000.00 to Thomas Jefferson University (doing business as Sidney Kimmel Medical College) to conduct research on the role of Alzheimer's disease risk genes in neural function, degeneration, and synapse organization. The research aims to enhance understanding of the shared mechanisms of synaptic maturation, determine how Alzheimer's-related mutations influence neurodegeneration, and...
The National Institute on Aging (NIA) awarded a $312,000 Project Grant (CFDA 93.866 - Aging Research) to The Medical College of Wisconsin, Inc. to investigate the impact of late-onset Alzheimer's disease (LOAD)-associated genes on neurodegeneration and Alzheimer's-related neurotoxicity using the C. elegans model system. The 2-year project, running from June 1, 2025 to May 31, 2027, aims to bridge the knowledge gap on the genetic basis of Alzheimer's disease by exploring how LOAD-associated genes...
The National Institute on Aging (NIA) awarded a $2,235,434 Project Grant (CFDA 93.866 - Aging Research) to the University of Washington to conduct research on the regulatory variation that affects splicing of the Alzheimer's disease risk gene TREM2. The project aims to:
Comprehensively characterize the TREM2 transcript repertoire in the human brain in health and disease.
Assess TREM2 variants in patients with dementia for their effect on RNA splicing and post-splicing processing.
Analyze the interplay between Alzheimer's disease-associated TREM2 regulatory variants and splicing factors perturbed in Alzheimer's brain.
The research will employ advanced techniques like long-read RNA sequencing, computational variant effect predictions, high-throughput screening, and quantitative proteomics to generate a high-resolution regulatory map of TREM2 that can be used to annotate the impact of genetic variants associated with Alzheimer's disease. The project is expected to run from Sep 30, 2024 to Jun 30, 2029.